Background and Objectives. Genicular nerve radiofrequency ablation is an effective treatment for patients with chronic pain due to knee osteoarthritis; however, little is known about factors that predict procedure success. The current study evaluated the utility of genicular nerve blocks to predict the outcome of genicular nerve cooled radiofrequency ablation (cRFA) in patients with osteoarthritis.
function up to six months following cRFA. A prognostic genicular nerve block using a local anesthetic volume of 1 mL at each injection site and a threshold of 50% pain relief for subsequent cRFA eligibility did not improve the rate of treatment success.
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Background
Chronic pain related to knee osteoarthritis (OA) is common, and if conservative and injection-based therapies fail to provide relief, this condition is frequently treated by total knee arthroplasty (TKA) [1] . However, many patients are poor candidates for TKA due to medical comorbidities or elect for nonsurgical management [2] . In other cases, patients may undergo TKA, yet more than 15% may experience persistent pain symptoms [3] . In response, partial sensory denervation of the anterior knee joint capsule by means of genicular nerve radiofrequency ablation (RFA) has been introduced as a solution to pain management in such cases. In the native knee, Choi et al. [4] have demonstrated the efficacy of genicular nerve RFA compared with sham treatment. Two randomized comparative investigation trials [5, 6] and multiple longitudinal cohort studies [7] [8] [9] [10] [11] [12] have confirmed the clinical effectiveness of this treatment for chronic pain related to knee OA.
Although genicular nerve RFA is a promising treatment option, little is known about factors that may predict success of this procedure, and no evidence-based algorithm has been established to facilitate appropriate candidate selection. In contrast, multiple studies describe the utility of nerve blocks to predict the long-term outcome of RFA for both zygaphophyseal joint [13] [14] [15] [16] [17] [18] and sacroiliac joint-mediated pain [19] [20] [21] . A similar evaluation of the utility of nerve block is needed with regard to patient selection for genicular nerve RFA, not only from a value-based health care approach, as has been investigated with regard to the use of prognostic nerve blocks prior to medial branch nerve RFA [22, 23] , but also to inform and educate patients regarding the long-term effectiveness of the procedure. The purpose of the current study was to evaluate the utility of prognostic genicular nerve blocks to predict the outcome of genicular nerve cooled radiofrequency ablation (cRFA) in patients with chronic pain due to knee OA. We hypothesized that a concordant reduction in knee pain by at least 50% following prognostic genicular nerve block compared with no prognostic genicular nerve block would be associated with improved pain, function, analgesic use, and patient satisfaction six months after cRFA treatment.
Methods
The study was approved by the Institutional Review Board of Northwestern University (STU00201206), and the protocol was registered at ClinicalTrials.gov (NCT02578108). This manuscript adheres to the Consolidated Standards of Reporting Trials (CONSORT) guidelines. This study was a prospective, randomized, comparative trial based on a superiority design conducted at Northwestern Memorial Hospital.
Inclusion criteria were 1) age between 30 and 80 years; 2) more than six months of knee pain; 3) lack of pain relief from conventional therapy, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, muscle relaxants, oral steroids, physical therapy, and intra-articular injection therapy; 4) numeric rating scale (NRS) pain score of 4 or greater (0 to 10, where 0 ¼ no pain and 10 ¼ worst pain imaginable); 5) Kellgren-Lawrence knee osteoarthritis grade of 2 or greater. Exclusion criteria were 1) refusal to participate, provide consent, or provide follow-up information for the six-month duration of the study; 2) pain referral beyond the expected distribution for knee osteoarthritis; 2) focal neurologic signs or symptoms; 3) concomitant radicular pain; 4) clinically significant cognitive deficit; 5) unstable medical or psychiatric illness; 6) previous radiofrequency ablation treatment for similar symptoms; 5) history of total or partial knee arthroplasty; 7) contraindication to genicular nerve block or genicular nerve cRFA (active infection, bleeding disorders, current anticoagulant or antiplatelet medication use, allergy to medications used in the protocol, pregnancy, pacemaker).
Eligible patients were screened and approached shortly after presentation to the Northwestern Memorial Hospital Pain Clinic. Screening included an assessment of the subject's medical history, history of knee pain, and current NRS score for pain. Patients meeting inclusion criteria provided informed written consent for study participation. Data were collected prior to study procedures using validated instruments: the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Short-Form McGill Pain Questionnaire (SF-MPQ), Hospital Anxiety and Depression Index (HADI), Medication Quantification Scale (MQS III) score, and daily opioid use in morphine equivalents. The MQS III is a validated measurement tool that yields a score derived from detriment ratings (based on physician survey) and dosing scores based on the physician desk reference [24] . The method of score calculation has been described in detail [24] . The MQSIII has been used in other clinical outcome studies intended to measure the effectiveness of an intervention for the treatment of chronic pain [11, [25] [26] [27] [28] .
Participants were randomly allocated to one of two study groups: to receive a prognostic genicular nerve block diagnostic block (PB) or not to receive a prognostic block (NPB). Prior to the study commencement, two-group block randomization was performed by an investigator (MCK) using a computer-generated allocation list. Group allocations were concealed in sequentially numbered opaque envelopes, which were opened by research personnel after the participant provided written informed consent.
The diagnostic and treatment procedures used in this study have been previously reported in detail [11] . Participants randomized to the PB group were positioned supine on a fluoroscopy table with the knee of interest in 30 to 40 degrees of flexion. Using a 25-gauge needle, a skin wheal of 1 mL of 1% lidocaine was used for local anesthesia. A 25-gauge 3.5-inch Whitacre needle was then advanced to three unique anatomic sites [29] to block the following neural structures: the superior lateral, the superior medial, and the inferior medial genicular nerves. Accurate and precise needle placement was confirmed using fluoroscopy in both the anteriorposterior and lateral planes. At each needle site, 1.0 mL of 2% lidocaine was injected in order to anesthetize each genicular nerve.
Participants allocated to the PB group were asked to maintain a pain log for the six hours following the prognostic blocks. Participants who reported at least 50% reduction in knee pain for at least one hour following blocks, allowing up to 30 minutes for the onset of lidocaine, underwent genicular nerve cRFA on a subsequent day. Participants in the PB group who reported less than 50% pain reduction or discordant pain reduction were offered treatment including cRFA but were not included in study.
Participant positioning for genicular nerve cRFA was identical to the genicular nerve block procedure. After applying noninvasive blood pressure and pulse oximetry monitors, sedation consisting of midazolam 1-2 mg IV and/or fentanyl 25-100 mcg IV was administered, with supplemental oxygen delivered via nasal cannula. Skin and soft tissues were anesthetized with 1 to 2 mL of 1% lidocaine at each of the three anatomic sites for cRFA. Three separate 50-or 75-mm 17-gauge introducer needles were then advanced to the target locations of the superior lateral, superior medial, and inferior medial genicular nerves [29] . The stylets were removed, and 1 mL of 2% lidocaine was injected through each of the introducer needles to anesthetize the region prior to thermal ablation. An 18-g internally cooled, 4-mm active tip RFA electrode (Coolief, Halyard Health, Alpharetta, GA, USA) was inserted through each of the introducer cannulae, and electrode positioning was verified with anteriorposterior and lateral fluoroscopic views. Each target was lesioned for 150 seconds at a programed temperature of 60 C, which creates a tissue temperature of 77 C according to ex vivo study [30] .
Immediately following the genicular nerve cRFA procedures, adverse events were recorded using a standardized questionnaire (Supplementary Data). At intervals of one month, three months, and six months after the cRFA procedure, assessments (NRS pain score, WOMAC, SF-MPQ, HADI, MQS III score, and daily opioid use in morphine equivalents) were obtained. In addition, the Patient Global Impression of Change (PGIC) score (values 1 to 7, where 1 ¼ very much improved, 2 ¼ improved, 3 ¼ slightly improved, 4 ¼ no change, 5 ¼ slightly worse, 6 ¼ worse, and 7 ¼ very much worse) was obtained. Participants were also questioned if they had undergone a total knee arthroplasty. Data collection at the follow-up intervals was performed by five (DD, RR, MK, TR, DR) researchers blinded to group assignment in person or by telephone.
The primary outcome was the proportion of participants with 50% or greater reduction in NRS pain score at the six-month follow-up assessment [31] . Worst-case scenario analysis was used to account for participants lost to follow-up, counting loss to follow-up as treatment failure. TKA following genicular nerve cRFA was also considered treatment failure. Secondary outcomes included NRS pain score, WOMAC, SF-MPQ, HADI, MQS III, and opioid consumption in daily morphine equivalents. Secondary outcomes were also defined based on "responder analysis" definitions of minimally clinically important change including a 15-point change on the WOMAC [32] , and PGIC score lower than 3 (indicating "improved" or "very much improved").
Statistical Analysis
The primary outcome, the proportion of participants reporting 50% reduction in pain at six months, was compared between the PB and the NPB groups using the Fisher exact test. Categorical clinical characteristics, prior pain procedures, and baseline use of opioid analgesics were compared using a chi-square statistic. Baseline use of opioid analgesics was a dichotomous variable. Baseline SF-MPQ, HADS, WOMAC, and MSQ II scores were compared using the Mann-Whitney U test. Change in NRS pain scores, SF-MPQ, HADS, and WOMAC scores following cRFA were compared with baseline using the Wilcoxon signed rank test, and confidence intervals of the median differences were calculated at 99% to account for multiple comparisons. Secondary outcomes PGIC, SF-MPQ, HADS, WOMAC, MSQ III, oral morphine equivalents, and NRS for pain were compared between the PB and the NPB groups at each follow-up interval using the Mann-Whitney U test. Data analysis was performed using RStudio, version 1.0.143 (RStudio: Integrated Development for R, RStudio, Inc., Boston, MA, USA; http://www.rstudio. com/) and R version 3.4.0 (release date April 21, 2017, The R Foundation for Statistical Computing, Vienna, Austria).
The sample size for this study was based on the findings of a prior randomized trial of genicular RFA vs genicular local anesthetic injection for chronic painful knee osteoarthritis [4] . In the aforementioned study, 59% of participants with one set of positive diagnostic blocks experienced 50% pain relief at six months. We estimated that the success rate would increase to 80% in participants who demonstrated 50% pain relief with a diagnostic block when cRFA was used, due to the larger lesion size, and thus the greater chance of successful neurolysis based on anatomic study [30] . Appropriate RFA technique has been associated with 80-95% pain and functional success rates in studies of medial branch neurotomy for facet joint denervation [17, [33] [34] [35] [36] . Group sample sizes of 33 participants would achieve a power of 80% to detect a difference of 35% in the proportion of participants who achieved 50% or more reduction in pain at six months between groups at a targeted alpha of 0.05 using the two-sided Fisher exact test. Sample size calculations were performed using PASS 2014 (NCSS, LLC, Kaysville, UT, USA).
Results
Between October 2015 and October 2016, 92 patients were screened for study eligibility. Sixty-seven patients met the inclusion criteria, and 63 subjects were randomized (32 to the PB group and 31 to the NPB group). Twenty-nine participants (36 knees) had cRFA following a successful diagnostic nerve block in the PB group, and 25 participants (35 knees) had cRFA in the NPB group. The flow of study participants is shown in Figure  1 . Baseline clinical characteristics, pain assessments, prior pain procedures, and analgesic use are shown in Table 1 . There were no differences in quality of life, knee disability, use of analgesic, or opioid use between the groups. Although there was no difference in knee pain reported, the duration of knee pain prior to cRFA was shorter in the PB group.
Seventeen participants (58.6%) in the prognostic block group and 16 (64.0%) in the no prognostic block group had 50% pain relief at six months (P ¼ 0.34). A 15-point decrease in the WOMAC index at six months was present in 17 of 29 (55%) in the prognostic block group and 15 of 25 (60%) in the no prognostic block group (P ¼ 0.36). The PGIC was reported as "improved" or "very much improved" in nine of 29 (31%) of the participants in the prognostic block group compared with nine of 25 (36%) in the no prognostic block group at six months (P ¼ 0.65). Only three of 29 participants (10%) in the prognostic block group and two of 25 (8%) participants in the no prognostic block group reported a PGIC of worse or very much worse at one month or six months (P ¼ 0.39).
Group comparisons and subscales of PGIC, SF-MPQ, HADS, and the WOMAC index at the follow-up intervals are shown in the Supplementary Data. There was a significant decrease in NRS pain scores and WOMAC functional assessments at the follow-up assessments compared with baseline within each group, but no difference between groups (Figure 2 ). There was no difference in the SF-MPQ between baseline and follow-up assessments within groups. Analgesia use as assessed using the MQS III was unchanged in either group throughout the study period ( Figure 3 ). The percentage of participants taking opioid analgesics and the total oral morphine equivalent dose of opioids was not changed from baseline in either group.
Exploratory analysis of the relationship between the percentage of pain relief from the prognostic block and the proportion of individuals who met responder analysis criteria for success of NRS (50% decrease from baseline), a PGIC score lower than 3 (indicating "improved" or "very much improved"), and a clinically important change (15-point) in the WOMAC knee assessment is shown in Table 2 . The percentage of participants who met the criteria for a successful outcome was increased at prognostic block improvement levels of 80% and 90% compared with 50%; however, the increase in participants with 50% reduction in NRS even at a prognostic block improvement of 90% was not different than at 50% relief (difference ¼ 18%, 95% CI of the difference ¼ -12% to 49%, P ¼ 0. 19) .
Discussion
This study demonstrated that genicular nerve cRFA was able to produce clinically significant improvements in knee pain and function scores at six-month follow-up in participants with chronic pain due to knee osteoarthritis. We did not observe a change in pain quality (SF-MPQ scores) or a reduction in analgesic use with the improvements demonstrated in pain and knee function. Selection of patients for cRFA using a prognostic block response threshold of 50% pain relief did not result in improved pain and knee function outcomes compared with cRFA performed in patients without screening by means of prognostic block, but by history, physical examination, and imaging studies alone. Unexpectedly, only three participants who received prognostic blocks reported less than 50% pain reduction, and thus, few participants in the prognostic block group were excluded from undergoing subsequent cRFA. This suggests that a block paradigm using 1 mL of local anesthetic volume at each genicular nerve site and a 50% threshold of minimum pain relief provides little prognostic value.
Because of this unexpected finding, we performed a post hoc sensitivity analysis of increasing minimum pain relief thresholds associated with a prognostic block (Supplementary Data). This exploratory analysis demonstrated an increasing proportion of successful response to cRFA as the threshold for selection increases from 50% to 90% relief following prognostic genicular nerve block. However, it must be acknowledged that this study was not powered to detect a difference in clinical outcomes within the group that received a prognostic block. Previous investigation has compared the predictive value of escalating thresholds for defining a "positive" block to increase the change of a successful outcome following medial branch nerve RFA; such studies have shown mixed results with regard to the benefit of increasing this threshold beyond 50% [13] [14] [15] [16] . We suspect that a more stringent prognostic block response threshold (80% or 90%) will result in a higher rate of success following genicular nerve cRFA given our preliminary findings, yet a larger study is necessary to confirm this hypothesis.
Furthermore, given the observed 40% treatment failure rate even when using a threshold of 90% pain relief associated with prognostic genicular nerve block, investigation of a dual-block paradigm is warranted. Parallel literature on diagnostic medial branch nerve blocks also demonstrates a high false-positive rate associated with a single block in both the cervical (27%) [37] and lumbar spine (38%) [38] ; these false-positive rate decrease The horizontal line is the median, the box ceiling and floor are the 25th and 75th percentiles, the whiskers are the 10th and 90th percentiles, and the circle is the 5th and 95th percentiles. *Different from baseline corrected for three comparisons. There were no between-group differences at any time point. In both the prognostic block and no prognostic block groups, median NRS scores for pain and median WOMAC scores were reduced from baseline at one month, three months, and six months (all P < 0.01 For the box plots, the horizontal line is the median, the box ceiling and floor are the 25th and 75th percentiles, the whiskers are the 10th and 90th percentiles, and the circle is the 5th and 95th percentiles. There were no differences between groups or between baseline and follow-up assessments within groups. MQS III ¼ Medication Quantification Scale Version III.
substantially with the addition of a second comparative block [37, 38] .
The observed suboptimal predictive value of genicular nerve blocks using the protocol described here may also be related to incongruence between the area anesthetized by the blocks and the area subsequently lesioned during the RFA procedure. In the present study, 1 mL of local anesthetic was injected at each target genicular nerve site during the prognostic block procedure because this volume has been described in other publications and is commonly used in clinical practice [9, 11] . However, 1 mL of anesthetic injected at each target genicular nerve site likely spreads beyond the boundaries a single RFA lesion. It is possible that periarticular nerves, aside from those targeted using the common genicular nerve RFA technique [4, 29] , are anesthetized by 1-mL injections, but then are not captured by the RFA lesions. Indeed, cadaver studies have demonstrated additional peri-articular nerves [39] [40] [41] , aside from those typically targeted with RFA based on dissections by Franco et al. [29] , that may contribute to the sensory innervation of the knee. Thus, investigation of appropriate anesthetic volume injected during prognostic blocks is needed, and further clinical outcome study of genicular nerve RFA that includes additional sensory nerve targets is warranted.
Inadequate nerve destruction of the intended genicular nerve targets may also contribute to the suboptimal success rate of this procedure, particularly in comparison with medial branch nerve RFA for facetogenic pain [17, [33] [34] [35] [36] . Variability in the location of the genicular nerves exists between individuals [28, 42] , thus when landmark-based RFA electrode placement is performed using fluoroscopic guidance, partial or incomplete lesioning may be possible. One study suggests that ultrasound guidance of the RFA electrode placement, with direct visualization of the nerves or their accompanying blood vessels, as opposed to using anatomic landmarks with fluoroscopic guidance alone, will increase the chance of successful genicular nerve destruction [42] .
The overall success rate in the present study (44%, 95% CI ¼ 32-56%) is higher than that of our previously published cross-sectional cohort study of genicular nerve cRFA for chronic pain due to knee OA (35%, 95% CI ¼ 22-48%) [11] . Given similar baseline characteristics, patient selection criteria, procedure technique, and loss to follow-up (counted as treatment failure), this difference may be related to a shorter follow-up duration in the present investigation (six months) compared with the prior study (median eight months). This finding suggests the need for longer-term prospective outcome measurement following genicular nerve cRFA to determine the durability of successful treatment. Comparative prospective study of treatment durability when using conventional thermal RFA rather than cRFA is also needed, as the alternative geometry of the cRFA lesion [30, 43] may produce a longer segment or more complete genicular neurolysis compared with conventional thermal RFA. Success rates at six-month follow-up vary from 10-60% with genicular neurolysis using conventional thermal RFA [4, 7, 12] . One study has assessed outcomes up to one year and demonstrated a 32% success rate, defined by a 50% reduction pain score [12] .
The limitations of the present study must be acknowledged. Participants in the prognostic block group had a shorter average duration of pain compared with participants who were randomized to forgo a diagnostic block. Shorter duration of pain is an independent predictor of the genicular nerve cRFA treatment success [11] . Participants were not blinded to group assignment; the group that did not receive prognostic blocks did not have sham injections, which introduces the possibility of response bias.
In conclusion, this prospective trial demonstrated clinically meaningful improvement in pain, physical function, and psychological function at up to six months for nearly half of participants who underwent genicular nerve cRFA for chronic pain related to knee osteoarthritis. However, prognostic genicular nerve block using a local anesthetic volume of 1 mL at each injection site and a threshold of 50% pain relief for subsequent cRFA eligibility did not improve the rate of treatment success.
